THERAPY DOSSIER · th-f6e299bdcf56

Chondroitinase ABC with or without stromal cell-derived factor 1 alpha, delivered from a crosslinked methylcellulose hydrogel

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28453954 ↗2017Mixed findings

Local delivery of chondroitinase ABC with or without stromal cell-derived factor 1alpha promotes functional repair in the injured rat spinal cord.

RatSpinal cord injuryCompressionSprague-DawleyFemaleLocalised intrathecal delivery from crosslinked methylcellulose hydrogel with embedded polymeric nanoparticlesAcute treatment after injury

Model: Impact-compression spinal cord injury

Chondroitinase ABC alone or combined with stromal cell-derived factor 1 alpha produced faster and more sustained behavioural improvement with reduced chondroitin sulphate proteoglycans and wider neural precursor cell distribution, while stromal cell-derived factor 1 alpha alone had no apparent effe…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…